Ceribell (CBLL) Net Income towards Common Stockholders (2023 - 2026)
Ceribell (CBLL) reported Net Income towards Common Stockholders of -$19.7 million for Q1 2026, down 54.47% on a YoY basis from -$43.4 million in Q1 2025, and down 45.91% quarter-over-quarter from -$13.5 million in Q4 2025.
Ceribell (CBLL) Net Income towards Common Stockholders (2023 - 2026) Analysis & Trends
Ceribell has reported Net Income towards Common Stockholders for 4 years, with the latest figure at -$19.7 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 54.47% year-over-year to -$19.7 million; the trailing twelve-month figure through Mar 2026 stood at -$60.4 million (down 35.03% YoY), and the FY2025 full-year result was -$53.4 million, down 32.03% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$19.7 million, down from -$13.5 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was -$7.1 million in Q3 2023, with the low at -$19.7 million in Q1 2026.
- Historically, Net Income towards Common Stockholders has averaged -$11.7 million across 4 years, with a median of -$12.6 million in 2024.
- Annual changes were most pronounced in 2025 — Net Income towards Common Stockholders slipped 7.56% — and 2026, when it tumbled 54.47%.
- Ceribell's Net Income towards Common Stockholders stood at -$8.3 million in 2023, then sank by 51.99% to -$12.6 million in 2024, then decreased by 7.56% to -$13.5 million in 2025, then slumped by 45.91% to -$19.7 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$19.7 million (Q1 2026), -$13.5 million (Q4 2025), and -$13.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.92 Bn | 146.27 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 119.50 Bn | 116.62 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 102.71 Bn | 94.54 Bn | 5.76 Bn | 1.15 Bn |
| 4 | Boston Scientific | 69.72 Bn | 68.51 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 49.24 Bn | 45.57 Bn | 1.29 Bn | - |
| 6 | GE HealthCare Technologies | 29.74 Bn | 27.67 Bn | 1.98 Bn | 411.00 Mn |
| 7 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 187,319.30 |
| 8 | Dexcom | 28.96 Bn | 27.84 Bn | 750.30 Mn | 199.50 Mn |
| 9 | Steris | 20.31 Bn | 19.88 Bn | 697.10 Mn | - |
| 10 | Ceribell | 695.83 Mn | 554.65 Mn | 23.12 Mn | -19.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.74 Mn |
| Dec 31, 2025 | -13.53 Mn |
| Sep 30, 2025 | -13.47 Mn |
| Jun 30, 2025 | -13.64 Mn |
| Mar 31, 2025 | -12.78 Mn |
| Dec 31, 2024 | -12.58 Mn |
| Sep 30, 2024 | -10.42 Mn |
| Jun 30, 2024 | -8.94 Mn |
| Mar 31, 2024 | -8.52 Mn |
| Dec 31, 2023 | -8.27 Mn |
| Sep 30, 2023 | -7.05 Mn |